ZJU index predicts diabetes progression and normoglycemia reversion in 11,243 individuals with impaired fasting glucose.
This retrospective multicenter cohort study included 11,243 individuals with impaired fasting glucose enrolled in a health screening program. The primary outcomes assessed were progression to diabetes and reversion to normoglycemia. Safety data, including adverse events and tolerability, were not reported in this analysis.
Results indicated that each one-unit increase in the ZJU index was associated with a 3% lower hazard of reversion to normoglycemia. Conversely, each one-unit increase in the ZJU index was associated with a 12% higher hazard of progression to diabetes. Absolute numbers and p-values were not reported for these associations.
The study did not report safety outcomes, discontinuations, or specific tolerability profiles for the index application. Limitations include the observational nature of the design and the absence of reported follow-up duration. Consequently, causal inferences cannot be drawn, and the findings should be viewed as associations rather than definitive clinical effects.
Despite these limitations, the ZJU index can serve as a practical tool for risk stratification and precision management in clinical settings. Clinicians should interpret these hazard ratios with caution given the lack of randomized evidence and missing safety data.